文献速递肿瘤 PET/CT放射性药物与辐射防护

68Ga-DOTA-Siglec-9靶向VAP-1的PET示踪剂首次人体研究

First-in-Humans Study of 68Ga-DOTA-Siglec-9, a PET Ligand Targeting Vascular Adhesion Protein 1.
PubMed 文献 · J Nucl Med · 2020-08-17

本研究首次在人体评价68Ga-DOTA-Siglec-9的安全性、生物分布与辐射剂量学。6名健康男性接受动态全身PET/CT,并在一例早期类风湿关节炎患者中与18F-FDG对比。该示踪剂耐受良好,血液清除快,有效剂量0.022 mSv/MBq,检测关节炎能力与18F-FDG相当。

要点

  • 68Ga-DOTA-Siglec-9静脉注射安全且耐受良好。
  • 平均有效剂量0.022 mSv/MBq,注射150 MBq约3.3 mSv。
  • 检测关节炎能力与18F-FDG相当。

核心结论

  • 68Ga-DOTA-Siglec-9静脉注射安全,生物分布适合在更大类风湿关节炎患者群中进一步试验。
  • 其有效辐射剂量与其他68Ga标记示踪剂范围相当,支持可能的重复临床使用。

研究设计与样本

  • 首次人体研究,6名健康男性接受动态全身PET/CT,静脉注射162 ± 4 MBq的68Ga-DOTA-Siglec-9。
  • 注射后1至240分钟系列采血,进行γ计数和高效液相色谱分析以检测完整示踪剂和放射性代谢物。
  • 使用OLINDA/EXM软件2.2版计算辐射剂量。
  • 另研究一例早期类风湿关节炎患者,同时接受68Ga-DOTA-Siglec-9和18F-FDG PET/CT以确定新示踪剂检测关节炎的能力。

主要发现

  • 68Ga-DOTA-Siglec-9在所有受试者中耐受良好。
  • 68Ga-DOTA-Siglec-9从血循环中快速清除,检测到数种放射性代谢物。
  • 吸收剂量最高的器官为膀胱壁(0.38 mSv/MBq)和肾脏(0.054 mSv/MBq)。
  • 平均有效剂量为0.022 mSv/MBq(范围0.020-0.024 mSv/MBq)。
  • 68Ga-DOTA-Siglec-9检测关节炎的能力与18F-FDG相当。

关键数值与推荐

  • 注射150 MBq的68Ga-DOTA-Siglec-9将使受试者暴露于3.3 mSv。
  • 膀胱壁吸收剂量0.38 mSv/MBq,肾脏吸收剂量0.054 mSv/MBq。
  • 平均有效剂量0.022 mSv/MBq(范围0.020-0.024 mSv/MBq)。

临床怎么用

  • 该示踪剂安全且辐射剂量与其他68Ga标记示踪剂相当,支持在类风湿关节炎患者中进一步试验。
  • 其检测关节炎能力与18F-FDG相当,可能用于阐明新药候选物的治疗疗效。

局限性

  • 健康受试者仅6名男性,患者仅一例早期类风湿关节炎。
  • 原文未报告示踪剂在更大患者群中的诊断准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sialic acid-binding immunoglubulinlike lectin 9 (Siglec-9) is a ligand of vascular adhesion protein 1. A 68Ga-labeled peptide of Siglec-9, 68Ga-DOTA-Siglec-9, holds promise as a novel PET tracer for imaging of inflammation. This first-in-humans study investigated the safety, tolerability, biodistribution, and radiation dosimetry of this radiopharmaceutical. Methods: Six healthy men underwent dynamic whole-body PET/CT. Serial venous blood samples were drawn from 1 to 240 min after intravenous injection of 162 ± 4 MBq of 68Ga-DOTA-Siglec-9. In addition to γ-counting, the plasma samples were analyzed by high-performance liquid chromatography to detect intact tracer and radioactive metabolites. Radiation doses were calculated using the OLINDA/EXM software, version 2.2. In addition, a patient with early rheumatoid arthritis was studied with both 68Ga-DOTA-Siglec-9 and 18F-FDG PET/CT to determine the ability of the new tracer to detect arthritis. Results:68Ga-DOTA-Siglec-9 was well tolerated by all subjects. 68Ga-DOTA-Siglec-9 was rapidly cleared from the blood circulation, and several radioactive metabolites were detected. The organs with the highest absorbed doses were the urinary bladder wall (0.38 mSv/MBq) and kidneys (0.054 mSv/MBq). The mean effective dose was 0.022 mSv/MBq (range, 0.020-0.024 mSv/MBq). Most importantly, however, 68Ga-DOTA-Siglec-9 was comparable to 18F-FDG in detecting arthritis. Conclusion: Intravenous injection of 68Ga-DOTA-Siglec-9 was safe and biodistribution was favorable for testing of the tracer in larger group of patients with rheumatoid arthritis, as is planned for the next phase of clinical trials. The effective radiation dose of 68Ga-DOTA-Siglec-9 was within the same range as the effective radiation doses of other 68Ga-labeled tracers. Injection of 150 MBq of 68Ga-DOTA-Siglec-9 would expose a subject to 3.3 mSv. These findings support the possible repeated clinical use of 68Ga-DOTA-Siglec-9, such as in trials to elucidate the treatment efficacy of novel drug candidates.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Viitanen R, Moisio O, Lankinen P, et al. First-in-Humans Study of 68Ga-DOTA-Siglec-9, a PET Ligand Targeting Vascular Adhesion Protein 1. J Nucl Med. 2020. PMID: 32817143. doi:10.2967/jnumed.120.250696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。